Houston pipeline heirs strike it rich as wealthiest family in Texas

AMERICA'S WEALTHIEST FAMILIES

Randa Williams is the high-profile heir of the Duncan family. Photo courtesy of Texas Monthly

Missouri has the Busches. Nebraska has the Buffetts. New York has the Hearsts. These are among the best-known wealthy families in the U.S.

Lesser-known nationally but well-known in Texas is the Duncan family of Houston, identified by FamilyMinded.com as the richest family in Texas. The website, which rounded up a list of the richest family in each state, pegs the family's estimated net worth at $26 billion; Forbes puts it at $25.6 billion.

The Duncan family comprises the four children of the late pipeline mogul Dan Duncan.

The children — Dannine Avara, Scott Duncan, Milane Frantz, and Randa Williams — inherited a tax-free $10 billion share of their father's estate following his death in 2010, when the so-called "death tax" had temporarily been repealed, according to Forbes. Each of them has an estimated net worth of $6.4 billion, Forbes says.

Williams is perhaps the most visible of the four Duncan heirs.

Williams is the only Duncan sibling who's involved in running the family business. She is chairwoman of Houston-based Enterprise Products Partners LP, the pipeline company that her father founded in 1968. Last year, the company posted revenue of $36.5 billion. In June, Williams made a big splash with her purchase of Austin-based Texas Monthly magazine.

While the Duncans are worth close to $26 billion, their wealth doesn't come close to that of Alice Walton of Fort Worth, the richest person in Texas. Forbes estimates her net worth at $52.4 billion.

FamilyMinded.com lists Alice Walton and her fellow heirs to the Walmart fortune as the richest family in Arkansas (where Walmart is based), with an estimated net worth of $163 billion. They're also the richest family in the U.S.

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.